Friday, 19 Jul 2019

You are here

Intraarticular Trans-Capsaicin Effective in Knee OA

A novel study has shown that intraarticular therapy with high‐purity synthetic trans‐capsaicin (CNTX‐4975) for chronic knee osteoarthritis (KOA) was associated with significant relief of knee pain.

The TRIUMPH study was a double‐blind, phase 2 study in adults (45–80 years) with stable knee osteoarthritis. Patients were given an intra‐articular injection of placebo, CNTX‐4975 0.5 mg, or CNTX‐4975 1.0 mg. The primary efficacy endpoint was area under the curve (AUC) for change in the WOMAC pain with walking scores at week 12.

A total of 172 subjects were enrolled and at week 12, greater decreases in WOMAC pain scores were observed with CNTX‐4975 versus placebo.

  • CNTX-4975 0.5 mg: LSMD, −0.79; P = 0.0740;
  • CNTX-4975 1.0 mg: LSMD, −1.6; P < 0.0001).  Efficacy continued till week 24 in the 1.0‐mg group (LSMD, −1.4; P = 0.0002.

Adverse events were similar in the placebo and 1.0‐mg groups.

Knee pain from KOA may be effectively and safely managed with this new investigational compound, CNTX‐4975 and is thought to be mediated by sustained desensitization of nociceptors (pain sensory fibers).

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Intraarticular Capsaicin in Knee Osteoarthritis

A novel compound, synthetic trans‐capsaicin (CNTX‐4975), has been studied as an intraarticular injection and shown to significantly reduce pain in patients with chronic moderate‐to‐severe osteoarthritis of the knee. A phase II, multicenter, double‐blind study enrolled 172 knee OA patients between the ages of 45–80 years. Patients were randomized to receive either intraarticular placebo, or a high‐purity synthetic trans‐capsaicin CNTX‐4975 0.5 mg, or CNTX‐4975 1.0 mg.

Increased Risk of Cardiovascular Death in Hip and Knee Osteoarthritis

Hip and knee osteoarthritis patients have been shown to have increased mortality rates from cardiovascular events when compared to the general population.

The study included patients in the Skåne Healthcare Register from southern Sweden who were 45–84 years old and seen over 2004-2014. Overall, there were 15,901 such patients in the study.

Safety Concerns Offset the Modest Improvements of Tanezumab in Osteoarthritis

JAMA reports that although tanezumab is modestly effective in moderate to severe osteoarthritis (knee or hip), with statistically significant improvements in pain and physical function, the tanezumab (TNZ) treated patients had more joint safety events and total joint replacements than patients treated with placebo.

Benefits vs Harms for Osteoporosis Drug Continuation or Discontinuation

While it is clear that long-term bisphosphonate therapies reduce fracture risk in women with osteoporosis, it is unclear how to counter-balance these benefits against rare serious harms and how to optimize therapeutic benefits with appropriate drug holidays. A systematic analysis of 48 studies compared long-term osteoporosis drug treatment (ODT) (>3 years) versus control versus ODT continuation versus durg discontinuation, to examine incident fractures or harms.

Mortality from Falls in the Elderly

JAMA reports that there is a trend of increasing mortality from falls in older US adults between 2000 to 2016 and that mortality rates are increased with increasing age.